8-K filed Jul 29, 2026 at 06:33 ET
Boston Scientific reported Q2 2026 adjusted EPS of $0.86, beating the $0.83 consensus by 3.6%, on revenue of $5.442B (7.5% reported growth, above the 5.5-7.5% guidance range). However, the company significantly lowered full-year 2026 guidance: organic revenue growth cut to 5-6% (from prior 6.5-8%) and adjusted EPS guidance reduced to $3.28-$3.32 (from $3.34-$3.41). The beat was overshadowed by the guidance cut and a 2-day-old restructuring plan (Item 2.05) with $700M-$800M in charges, signaling a material deceleration in the core business.